APOB and Hepatic steatosis: We have previously shown that mice with a hepatocyte-specific deletion of PPARα (PparaHepKO) had worsened hepatic steatosis on a HFD that also caused significantly higher plasma triglycerides and ApoB100 levels (Stec et al., 2019).